What Happened
Akorn, Inc. AKRX shares fell more than 30 percent Monday evening after Fresenius Kabi AG announced an independent investigation into alleged breaches of FDA data integrity requirements related to product development.
Akorn later released a statement confirming its active participation in the probe.
Why It’s Important
The outcome of the investigation may derail a deal between the companies that saw Fresenius buying Akorn for $34 per share. The acquisition was announced in April 2017 and has yet to close.
Akorn assured investors that the transaction should continue as planned.
“To date, the Company's investigation has not found any facts that would result in a material impact on Akorn's operations and the Company does not believe this investigation should affect the closing of the transaction with Fresenius,” the statement read.
What’s Next
Fresenius noted that it will not provide updates throughout the investigation, but it will continue to seek regulatory clearance for the merger from the Federal Trade Commission.
At time of publication, Akorn shares had marginally recovered and were set to open down 28.7 percent around $21.60.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.